MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards
1.11.2024 13:37:00 CET | Business Wire | Press release
Palace fans can now download the MyGuava App and order a custom- designed Crystal Palace Card.Cards will provide users with cashback on all purchases, with up to 7% available for limited edition cards at any sporting goods store.900 ‘Palace Gold’ cards will also be made available, with each card providing the user with enhanced cashback and exclusive club benefits.
MyGuava in association with Crystal Palace Football Club is thrilled to launch exclusive Crystal Palace Fan Cards with rewards and a variety of perks as well as a unique opportunity for fans to celebrate their connection to the club while enjoying MyGuava’s seamless payment solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101068560/en/
MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards (Photo: Business Wire)
Palace fans can now download the MyGuava App and order a Crystal Palace Card, choosing from three custom-designed cards: ‘Palace Gold’, ‘Palace Sash’ and ‘Selhurst 100’.
Each card comes packed with perks, including entry into exclusive prize draws, cashback on all purchases, giving Palace fans an opportunity to take advantage of the 7% cashback offer ahead of the festive period. Additionally, the cards come with Visa Platinum status for added financial flexibility.
Furthermore, for the most dedicated Eagles supporters, 900 limited-edition ‘Palace Gold’ cards will be available on a first come first served basis, offering enhanced cashback rates and special access to exclusive club benefits.
Rewards System
The MyGuava and Crystal Palace card will also be introducing a multi-stage reward system, providing cardholders with the exciting chance to earn Crystal Palace merchandise and experience based on spending. Supporters can win Crystal Palace branded bottles, t-shirts, hoodies as well as stadium tours and even personalised messages from the team for completing transaction milestones.
The MyGuava App, which is the flagship product of Guavapay, is designed to meet the broad financial needs of users. Users can open accounts in 20 currencies, make seamless local and global transfers, and use both virtual and physical debit cards. The App also has significant global reach, with access to 140 countries in more than 90 currencies and there are additional benefits with discounted gift cards from top brands and tools for enhancing user experience, such as digital skins, spending management tools and vaults.
To learn more about the Crystal Palace Card and Reward scheme, please visit the link below:
https://myguava.com/personal/landings/crystalpalace-cobrand-card
About Guavapay
Guavapay is a global fintech company with headquarters in London. The company has built a global financial ecosystem to empower individuals and businesses and give them more control over their financial lives. The All Things Payments App, MyGuava and the B2B platform, MyGuava Business simplify financial services, making them more accessible and affordable for people who have historically been overlooked.
The MyGuava Application is owned and operated by Guavapay Limited, a company registered in England with company number 10601900 and its registered address at Salisbury House, 29 Finsbury Circus, London, EC2M 5QQ, United Kingdom. Guavapay Limited is registered with the Financial Conduct Authority in the United Kingdom as a Small Electronic Money Institution with reference number 900888. Guavapay Limited’s ICO registration number is ZA274504.
For more information, please visit www.guavapay.com or contact:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101068560/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom